NeuroOne® to Report First Quarter Fiscal Year 2024 Financial Results and Provide Corporate Update on February 13
February 08, 2024 15:30 ET
|
NeuroOne Medical Technologies Corp
EDEN PRAIRIE, Minn., Feb. 08, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving...
NeuroOne® Reports Fiscal Fourth Quarter and Full Fiscal Year 2023 Financial Results and Provides Corporate Update
December 14, 2023 16:15 ET
|
NeuroOne Medical Technologies Corp
EDEN PRAIRIE, Minn., Dec. 14, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving...
NeuroOne® to Report Fourth Quarter and Fiscal Year 2023 Financial Results and Provide Corporate Update on December 14
December 07, 2023 16:30 ET
|
NeuroOne Medical Technologies Corp
EDEN PRAIRIE, Minn., Dec. 07, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving...
NeuroOne® Announces Patent Allowance for Drug Delivery Utilizing a Novel Neural Probe
November 16, 2023 08:00 ET
|
NeuroOne Medical Technologies Corp
Patent allowance strengthens IP portfolio and positions company in pursuing drug delivery using its neural probes EDEN PRAIRIE, Minn., Nov. 16, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical...
NeuroOne® Appoints Medtech Executive Christopher R. Volker as Chief Operating Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 14, 2023 17:15 ET
|
NeuroOne Medical Technologies Corp
Volker strengthens existing management team in areas of commercialization, business development, and reimbursement EDEN PRAIRIE, Minn., Nov. 14, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical...
NeuroOne® Provides Progress Update on FDA 510(k) Submission for OneRF™ Ablation System
November 07, 2023 08:00 ET
|
NeuroOne Medical Technologies Corp
Feedback from responses to FDA anticipated in 30 days Commercialization remains on track in first half of 2024 pending FDA clearance Product potential for transformative improvement in...
NeuroOne® to Present at the ThinkEquity Conference on October 19, 2023
October 13, 2023 09:30 ET
|
NeuroOne Medical Technologies Corp
EDEN PRAIRIE, Minn., Oct. 13, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving...
NeuroOne® to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023 16:00 ET
|
NeuroOne Medical Technologies Corp
EDEN PRAIRIE, Minn., Sept. 06, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving...
NeuroOne® Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
August 14, 2023 16:00 ET
|
NeuroOne Medical Technologies Corp
EDEN PRAIRIE, Minn., Aug. 14, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving...
NeuroOne® to Report Third Quarter Fiscal Year 2023 Financial Results and Provide a Corporate Update on August 14
August 08, 2023 16:00 ET
|
NeuroOne Medical Technologies Corp
EDEN PRAIRIE, Minn., Aug. 08, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving...